Abstract
The new coronavirus infection (COVID-19) is considered a systemic disease, often complicated by thrombotic events, impacting respiratory, cardiovascular, gastrointestinal, hematopoietic, and immune systems. The development of a hypercoagulable state accompanying the disease involves inflammatory reactions, endothelial dysfunction, hemostatic system activation, and autoimmune disorders, including antiphospholipid antibodies (aPA). Despite the high prevalence of aPA in COVID-19 patients, its impact on thrombotic complications and disease outcome is not significant. The transient nature of these antibodies and conflicting study results suggest uncertainty about their influence on clinical outcomes in COVID-19 patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
